{
  "docId": "019de073-a7b5-7720-904b-d55cb9d2acd2",
  "docSlug": "ff09795c4205ae982e453519f0f2447b",
  "documentTitle": "Bionomics | Investor Presentation Deck | 59 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 59,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a list-based layout with icons to summarize key company highlights.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a7b5-7720-904b-d55cb9d2acd2/40",
  "deckHref": "/decks/019de073-a7b5-7720-904b-d55cb9d2acd2",
  "deckJsonHref": "/decks/019de073-a7b5-7720-904b-d55cb9d2acd2.json",
  "deckAnchorHref": "/decks/019de073-a7b5-7720-904b-d55cb9d2acd2#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0023
      },
      "kind": "list",
      "text": "Lead Asset BNC210: Potential for $1.7B Peak Sales in SAD and $2.6B Peak Sales in PTSD; IP coverage for BNC210 extending to late 2030s",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f1e2fca-048e-45e9-92ca-3c9bb9f01cd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0058
      },
      "kind": "list",
      "text": "Partnerships & Collaborations: Strategic partnership with Merck; MOU with EmpathBio; Pipeline of partnering candidates targeting potassium (Kv) and sodium (Nav) ion channels",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ad45a7f-4c4e-45c3-9650-fef5407840d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0013
      },
      "kind": "list",
      "text": "Targeting Social Anxiety Disorder (SAD), Post-Traumatic Stress Disorder (PTSD) and cognitive dysfunction associated with Alzheimer’s disease, schizophrenia and other CNS conditions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b29e35d7-59ed-4bd7-86e5-98ecaf9d4020",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0078
      },
      "kind": "list",
      "text": "Cash runway beyond multiple near-term catalysts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4cc9c3a-1efe-4968-9650-763584be8ecb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0035
      },
      "kind": "list",
      "text": "BNC210 (negative allosteric modulator of the α7 nicotinic acetylcholine receptor); Clinical proof of concept in Generalized Anxiety Disorder (GAD) and panic attack model; In Phase 2 PREVAIL trial with FDA Fast Track designation for acute treatment of SAD; In Phase 2b ATTUNE trial with FDA Fast Track designation for treatment of PTSD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f63318f3-fa1f-4a0a-be8c-a9d9a599c38f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.08,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "CNS = Central Nervous System; MOU = Memorandum of Understanding; 1. Bluestar BioAdvisors; 2. Wise et al 2020, Biological Psychiatry; Perkins et al 2021, Molecular Psychiatry",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da6a8a70-af00-4cfd-bfaf-9ba455e7c38f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.29,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Bionomics Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01a0afe9-4a85-4a28-9b9a-7465a1c81645",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 41,
      "from": 40,
      "name": "Pareto Focus",
      "slug": "50-pareto-focus",
      "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
      "matchId": "61205657-1167-458d-9778-2ccd92258447",
      "evidence": "The deck presents Bionomics' focus on BNC210 and its potential for growth.",
      "position": 2,
      "objective": "Highlight the focus of Bionomics on BNC210 and its potential",
      "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
      "confidence": 0.6,
      "description": "Show that 80% of results come from 20% of causes to drive prioritization"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}